Annual Statements Open main menu

KEWAUNEE SCIENTIFIC CORP /DE/ - Quarter Report: 2013 July (Form 10-Q)

Form 10-Q

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 10-Q

 

 

 

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended July 31, 2013

or

 

¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from                      to                     

Commission file number 0-5286

 

 

KEWAUNEE SCIENTIFIC CORPORATION

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   38-0715562

(State or other jurisdiction of

incorporation or organization)

 

(IRS Employer

Identification No.)

2700 West Front Street

Statesville, North Carolina

  28677-2927
(Address of principal executive offices)   (Zip Code)

Registrant’s telephone number, including area code: (704) 873-7202

 

 

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  x    No  ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).    Yes  x    No  ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definition of “large accelerated filer,” “accelerated filer,” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

 

Large accelerated filer   ¨    Accelerated filer   ¨
Non-accelerated filer   ¨  (Do not check if a smaller reporting company)    Smaller reporting company   x

Indicate by check mark whether the registrant is a shell company (as defined by Rule 12b-2 of the Exchange Act).    Yes  ¨    No  x

As of September 9, 2013, the registrant had outstanding 2,604,830 shares of Common Stock.

 

 

 


KEWAUNEE SCIENTIFIC CORPORATION

INDEX TO FORM 10-Q

FOR THE QUARTERLY PERIOD ENDED JULY 31, 2013

 

         Page Number  

PART I. FINANCIAL INFORMATION

  

Item 1.

 

Financial Statements

  
 

Consolidated Statements of Operations (unaudited)
– Three months ended July 31, 2013 and 2012

     1   
 

Consolidated Statements of Comprehensive Income (unaudited)
– Three months ended July 31, 2013 and 2012

     2   
 

Consolidated Statement of Stockholders’ Equity
– Three-months ended July 31, 2013 (unaudited)

     3   
 

Consolidated Balance Sheets – July 31, 2013 (unaudited) and April 30, 2013

     4   
 

Consolidated Statements of Cash Flows (unaudited)
– Three months ended July 31, 2013 and 2012

     5   
 

Notes to Consolidated Financial Statements

     6   

Item 2.

 

Management’s Discussion and Analysis of Financial Condition and Results of Operations

     7   
 

Review by Independent Registered Public Accounting Firm

     10   
 

Report of Independent Registered Public Accounting Firm

     11   

Item 3.

 

Quantitative and Qualitative Disclosures About Market Risk

     12   

Item 4.

 

Controls and Procedures

     12   

PART II. OTHER INFORMATION

  

Item 6.

 

Exhibits

     13   

SIGNATURE

     14   

 

i


Part 1. Financial Information

 

Item 1. Financial Statements

Kewaunee Scientific Corporation

Consolidated Statements of Operations

(Unaudited)

(in thousands, except per share data)

 

     Three months ended
July 31
 
     2013     2012  

Net Sales

   $ 32,003      $ 26,683   

Costs of products sold

     25,427        21,440   
  

 

 

   

 

 

 

Gross profit

     6,576        5,243   

Operating expenses

     4,144        4,138   
  

 

 

   

 

 

 

Operating earnings

     2,432        1,105   

Other income

     80        68   

Interest expense

     (88     (114
  

 

 

   

 

 

 

Earnings before income taxes

     2,424        1,059   

Income tax expense

     807        371   
  

 

 

   

 

 

 

Net earnings

     1,617        688   

Less: net earnings attributable to the noncontrolling interest

     30        54   
  

 

 

   

 

 

 

Net earnings attributable to Kewaunee Scientific Corporation

   $ 1,587      $ 634   
  

 

 

   

 

 

 

Net earnings per share attributable to Kewaunee Scientific Corporation stockholders

    

Basic

   $ 0.61      $ 0.25   

Diluted

   $ 0.61      $ 0.25   

Weighted average number of common shares outstanding

    

Basic

     2,596        2,581   

Diluted

     2,618        2,584   

See accompanying notes to consolidated financial statements.

 

1


Kewaunee Scientific Corporation

Consolidated Statements of Comprehensive Income

(Unaudited)

(in thousands)

 

     Three months ended
July 31
 
     2013     2012  

Net earnings

   $ 1,617      $ 688   
  

 

 

   

 

 

 

Other comprehensive income (loss), net of tax:

    

Foreign currency translation adjustments

     (524     (136

Change in fair value of cash flow hedge

     65        (12
  

 

 

   

 

 

 

Other comprehensive income (loss)

     (459     (148
  

 

 

   

 

 

 

Comprehensive income, net of tax

     1,158        540   

Less: comprehensive income attributable to the noncontrolling interest

     30        54   
  

 

 

   

 

 

 

Comprehensive income attributable to Kewaunee Scientific Corporation

   $ 1,128      $ 486   
  

 

 

   

 

 

 

See accompanying notes to consolidated financial statements.

 

2


Kewaunee Scientific Corporation

Consolidated Statement of Stockholder’s Equity

(Unaudited)

(in thousands)

 

$ in thousands, except per share amounts

   Common
Stock
     Additional
Paid-in
Capital
    Treasury
Stock
    Retained
Earnings
    Accumulated
Other
Comprehensive
Income (Loss)
    Total
Stockholders’
Equity
 

Balance at April 30, 2013

   $ 6,550       $ 1,567      $ (305   $ 31,191      $ (7,327   $ 31,676   

Purchase of noncontrolling interest (Note B)

     —          —         —         (1,874     —         (1,874

Net earnings

     —          —         —         1,587        —         1,587   

Other comprehensive income (loss)

     —          —         —         —         (459     (459

Cash dividends declared, $0.10 per share

     —          —         —         (260     —         (260

Stock options exercised, 13,500 shares

     —          (7     150        —         —         143   

Stock options granted, 10,000 shares

     —          59        —         —         —         59   

Purchase of treasury stock, 6,598 shares

     —          —         (86     —         —         (86
  

 

 

    

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Balance at July 31, 2013

   $ 6,550       $ 1,619      $ (241   $ 30,644      $ (7,786   $ 30,786   
  

 

 

    

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

See accompanying notes to consolidated financial statements.

 

3


Kewaunee Scientific Corporation

Consolidated Balance Sheets

(in thousands)

 

     July 31,
2013
    April 30,
2013
 
     (Unaudited)        

Assets

    

Current Assets:

    

Cash and cash equivalents

   $ 4,408      $ 5,811   

Restricted cash

     619        691   

Receivables, less allowance

     24,752        25,884   

Inventories

     12,334        13,203   

Deferred income taxes

     607        654   

Prepaid expenses and other current assets

     1,469        987   
  

 

 

   

 

 

 

Total Current Assets

     44,189        47,230   

Property, plant and equipment, at cost

     45,627        45,109   

Accumulated depreciation

     (30,632     (30,011
  

 

 

   

 

 

 

Net Property, Plant and Equipment

     14,995        15,098   

Deferred income taxes

     2,323        2,241   

Other

     4,352        4,173   
  

 

 

   

 

 

 

Total Other Assets

     6,675        6,414   
  

 

 

   

 

 

 

Total Assets

   $ 65,859      $ 68,742   
  

 

 

   

 

 

 

Liabilities and Equity

    

Current Liabilities:

    

Short-term borrowings and interest rate swap

   $ 5,101      $ 6,997   

Current portion of long-term debt

     455        200   

Accounts payable

     8,234        10,406   

Employee compensation and amounts withheld

     1,861        2,076   

Deferred revenue

     648        488   

Other accrued expenses

     3,117        1,948   
  

 

 

   

 

 

 

Total Current Liabilities

     19,416        22,115   

Long-term debt

     4,508        3,267   

Accrued pension and deferred compensation costs

     10,037        9,667   

Other non-current liabilities

     888        —    
  

 

 

   

 

 

 

Total Liabilities

     34,849        35,049   

Commitments and Contingencies

    

Equity:

    

Common Stock

     6,550        6,550   

Additional paid-in-capital

     1,619        1,567   

Retained earnings

     30,644        31,191   

Accumulated other comprehensive loss

     (7,786     (7,327

Common stock in treasury, at cost

     (241     (305
  

 

 

   

 

 

 

Total Kewaunee Scientific Corporation Stockholders’ Equity

     30,786        31,676   

Noncontrolling interest

     224        2,017   
  

 

 

   

 

 

 

Total Equity

     31,010        33,693   
  

 

 

   

 

 

 

Total Liabilities and Equity

   $ 65,859      $ 68,742   
  

 

 

   

 

 

 

See accompanying notes to consolidated financial statements.

 

4


Kewaunee Scientific Corporation

Consolidated Statements of Cash Flows

(Unaudited)

(in thousands)

 

     Three months ended
July 31
 
     2013     2012  

Cash flows from operating activities:

    

Net earnings

   $ 1,617      $ 688   

Adjustments to reconcile net earnings to net cash provided by operating activities:

    

Depreciation

     631        658   

Bad debt provision

     29        25   

Non-cash stock option expense

     59        64   

Provision for deferred income tax expense

     (35     (37

Decrease in receivables

     1,103        1,273   

Decrease in inventories

     869        43   

(Decrease) increase in accounts payable and other accrued expenses

     (2,105     768   

Increase (decrease) in deferred revenue

     160        (456

Other, net

     (523     (296
  

 

 

   

 

 

 

Net cash provided by operating activities

     1,805        2,730   

Cash flows from investing activities:

    

Capital expenditures

     (528     (434

Decrease in restricted cash

     72        51   
  

 

 

   

 

 

 

Net cash used in investing activities

     (456     (383

Cash flows from financing activities:

    

Dividends paid

     (260     (258

Decrease in short-term borrowings and interest rate swap

     (1,896     (315

Proceeds from long-term debt

     5,000        —    

Payments on long-term debt

     (3,504     (50

Payments on capital leases

     —         (21

Payment toward purchase of noncontrolling interest in subsidiary

     (1,780     —    

Net proceeds from exercise of stock options (including tax benefit)

     57        32   
  

 

 

   

 

 

 

Net cash used in financing activities

     (2,383     (612

Effect of exchange rate changes on cash

     (369     (203
  

 

 

   

 

 

 

(Decrease) increase in cash and cash equivalents

     (1,403     1,532   

Cash and cash equivalents, beginning of period

     5,811        6,188   
  

 

 

   

 

 

 

Cash and cash equivalents, end of period

   $ 4,408      $ 7,720   
  

 

 

   

 

 

 

Supplemental Disclosure of Cash Flow Information

    

Purchase of noncontrolling interest in subsidiary – other accrued expenses and other non-current liabilities

   $ 1,775      $ —    
  

 

 

   

 

 

 

See accompanying notes to consolidated financial statements.

 

5


Kewaunee Scientific Corporation

Notes to Consolidated Financial Statements

(unaudited)

A. Financial Information

The unaudited interim consolidated financial statements of Kewaunee Scientific Corporation (the “Company” or “Kewaunee”) have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (the “Commission”). Accordingly, certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted, although the Company believes that the disclosures are adequate to make the information presented not misleading.

These interim consolidated financial statements include all adjustments (consisting of normal recurring adjustments) necessary for a fair presentation of these financial statements and should be read in conjunction with the consolidated financial statements and notes included in the Company’s 2013 Annual Report to Stockholders. The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the full year. The consolidated balance sheet as of April 30, 2013 included in this interim period filing has been derived from the audited financial statements at that date, but does not include all of the information and related notes required by generally accepted accounting principles (GAAP) for complete financial statements.

The preparation of the interim consolidated financial statements requires management to make certain estimates and assumptions that affect reported amounts and disclosures. Actual results could differ from those estimates.

B. Purchase of Noncontrolling Interest

During the three-month period ended July 31, 2013, the Company entered into an Agreement (the “Agreement”) whereby it purchased the 49% minority ownership of its subsidiary, Kewaunee Labway Asia Pte. Ltd. (the “Subsidiary”) for a total purchase price of $3,555,000. The purchase was recorded in the equity section of the consolidated balance sheet as a $1,874,000 reduction in retained earnings and a $1,681,000 reduction in noncontrolling interest. Pursuant to the terms of the Agreement, the Company paid cash of $1,780,000 to the minority stockholder and recorded other current liabilities of $887,500 and other noncurrent liabilities of $887,500. The Subsidiary and its subsidiary in India, Kewanee Labway India Pvt. Ltd., serve as the Company’s principal sales and distribution organization for sales to international customers.

C. Earnings Per Share

Basic earnings per share is based on the weighted average number of common shares outstanding during the three month period. Diluted earnings per share reflects the assumed exercise and conversion of outstanding options under the Company’s stock option plans, except when options have an anti-dilutive effect. Options to purchase 72,850 and 237,675 shares were not included in the computation of diluted earnings per share for the three month periods ended July 31, 2013 and 2012, respectively, because the option exercise prices were greater than the average market price of the common shares at that date, and accordingly, such options would have an antidilutive effect.

D. Inventories

Inventories consisted of the following (in thousands):

 

     July 31, 2013      April 30, 2013  

Finished products

   $ 3,208       $ 4,052   

Work in process

     1,719         1,678   

Raw materials

     7,407         7,473   
  

 

 

    

 

 

 
   $ 12,334       $ 13,203   
  

 

 

    

 

 

 

For interim reporting, LIFO inventories are computed based on year-to-date quantities and interim changes in price levels. Changes in quantities and price levels are reflected in the interim consolidated financial statements in the period in which they occur.

E. Long-Term Debt and Other Credit Arrangements

On May 6, 2013, the Company entered into a new credit and security agreement (the “Loan Agreement”) with a new lender consisting of (1) a $20 million revolving credit facility which matures on May 1, 2016 (“Line of Credit”), (2) a term loan in the amount of $3,450,000 which matures on May 1, 2020 (“Term Loan A”) and (3) a term loan in the amount of $1,550,000 which matures on May 1, 2020 (“Term Loan B” and together with Term Loan A, the “Term Loans”). The Loan Agreement provided funds to refinance all existing indebtedness to the Company’s previous lender and for working capital and other general corporate purposes. In addition,

 

6


it provides for the issuance of up to $4.7 million of letters of credit for our account. Indebtedness under the Line of Credit bears interest at a variable rate per annum equal to Daily One Month LIBOR plus 1.5% per annum. Payments are due under Term Loan A in consecutive equal monthly principal payments in the amount of $17,000 until August 1, 2017, and then in consecutive equal monthly principal payments in the amount of $79,000 each, commencing on September 1, 2017 and continuing on the first business day of each month thereafter until May 1, 2020, and at that time, all principal, accrued unpaid interest and other charges outstanding under Term Loan A shall be due and payable in full. The interest rate on Term Loan A, after consideration of interest rate swap agreements, is a fixed rate per annum equal to 4.875%, and effective August 1, 2017, such rate converts to a fixed rate per annum of 4.37%. Payments are due under Term Loan B in consecutive equal monthly principal payments in the amount of $18,000 until May 1, 2020, and at that time, all principal, accrued unpaid interest and other charges outstanding under Term Loan B shall be due and payable in full. The interest rate on Term Loan B, after consideration of interest rate swap agreement, is a variable rate per annum equal to Daily One Month LIBOR plus 1.575% per annum, and effective November 3, 2014, such rate converts to a fixed rate per annum of 3.07%.

The credit facility includes financial covenants with respect to certain ratios, including (a) debt-to-net worth, (b) fixed charge coverage, and (c) asset coverage. At July 31, 2013, the Company was in compliance with all of the financial covenants. At July 31, 2013, there were advances of $4,862,000 outstanding under the revolving credit line.

F. Segment Information

The following table provides financial information by business segments for the three months ended July 31, 2013 and 2012 (in thousands):

 

     Domestic
Operations
     International
Operations
     Corporate     Total  

Three months ended July 31, 2013

          

Revenues from external customers

   $ 27,073       $ 4,930       $ —       $ 32,003   

Intersegment revenues

     1,404         486         (1,890     —    

Operating earnings (loss) before income taxes

     3,182         557         (1,315     2,424   

Three months ended July 31, 2012

          

Revenues from external customers

   $ 22,629       $ 4,054       $ —       $ 26,683   

Intersegment revenues

     730         504         (1,234     —    

Operating earnings (loss) before income taxes

     1,884         246         (1,071     1,059   

G. Defined Benefit Pension Plans

The Company has non-contributory defined benefit pension plans covering substantially all salaried and hourly employees. These plans were amended as of April 30, 2005, no further benefits have been, or will be, earned under the plans, subsequent to the amendment date, and no additional participants will be added to the plans. The Company did not make any contributions to the plans during the three months ended July 31, 2013 and July 31, 2012. The Company expects to make contributions in the amount of $300,000 to the plans in fiscal year 2014.

Pension expense consisted of the following (in thousands):

 

     Three months ended
July 31, 2013
    Three months ended
July 31, 2012
 

Service cost

   $ -0-      $ -0-   

Interest cost

     212        227   

Expected return on plan assets

     (317     (302

Recognition of net loss

     283        275   
  

 

 

   

 

 

 

Net periodic pension expense

   $ 178      $ 200   
  

 

 

   

 

 

 

H. Reclassifications

Certain 2012 amounts have been reclassified to conform with the 2013 presentation in the consolidated statements of cash flows. Such reclassifications had no impact on net earnings.

 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

The Company’s 2013 Annual Report to Stockholders contains management’s discussion and analysis of financial condition and results of operations at and for the year ended April 30, 2013. The following discussion and analysis describes material changes in the Company’s financial condition since April 30, 2013. The analysis of results of operations compares the three months ended July 31, 2013 with the comparable period of the prior year.

 

7


Results of Operations

Sales for the three months ended July 31, 2013 were $32,003,000, an increase from sales of $26,683,000 in the comparable period of the prior year. Sales from Domestic Operations were $27,073,000, up from sales of $22,629,000 in the comparable period of the prior year. Domestic sales benefited from strong order activity from the Company’s dealer network and a strong backlog with customer ship dates during the quarter. Sales from International Operations were $4,930,000, up from sales of $4,054,000 in the comparable period of the prior year. International operations sales benefited from increased opportunities in the international markets and the favorable timing of several projects.

The order backlog was $71.1 million at July 31, 2013, as compared to $80.2 million at April 30, 2013 and $86.7 million at July 31, 2012. The lower order backlog reflects several factors, including the composition of the Domestic backlog, which continues to transition to a higher percentage of orders received through the Company’s dealer organization. These orders typically remain in the backlog for a shorter duration. The backlog also reflects the manufacturing and shipment of a large International project during the quarter that had been in the backlog for an extended period due to construction project delays.

The gross profit margin for the three months ended July 31, 2013 was 20.5% of sales, as compared to 19.6% of sales in the comparable period of the prior year. The increase in the gross profit margin was primarily due to lower operating costs and increased efficiencies associated with the higher manufacturing volumes.

Operating expenses for the three months ended July 31, 2013 were $4,144,000, or 12.9% of sales, as compared to $4,138,000, or 15.5% of sales, in the comparable period of the prior year. Expenses in the current year period were favorably impacted by cost savings initiatives, which substantially offset an increase of $199,000 in performance incentive programs expense and variable expenses associated with the increase in sales.

Interest expense was $88,000 for the three months ended July 31, 2013, as compared to $114,000 for the comparable period of the prior year. The decrease for the current year period resulted from lower borrowing levels.

Income tax expense of $807,000 was recorded for the three months ended July 31, 2013, as compared to income tax expense of $371,000 recorded for the comparable period of the prior year. The effective tax rate was 33.3% for the three months ended July 31, 2013, and was 35.0% for the comparable period of the prior year. The lower effective tax rate for the current year period resulted primarily from a higher ratio of pretax earnings in the current period attributable to subsidiaries located in geographic locations with lower income tax rates.

Noncontrolling interests related to the Company’s two subsidiaries that were not 100% owned by the Company reduced net earnings by $30,000 for the three months ended July 31, 2013, as compared to a reduction of $54,000 for the comparable period of the prior year. As discussed in Note B, during the quarter ended July 31, 2013, the Company purchased the 49% minority ownership of one of its subsidiaries. The purchase of the minority ownership and reduction of the noncontrolling interest had a favorable impact on net earnings of $140,000 for the three months ended July 31, 2013.

Net earnings were $1,587,000, or $0.61 per diluted share, for the three months ended July 31, 2013. This compares to net earnings of $634,000, or $0.25 per diluted share, for the comparable period of the prior year.

Liquidity and Capital Resources

Historically, the Company’s principal sources of liquidity have been funds generated from operations, supplemented as needed by short-term borrowings under the Company’s revolving credit facility. Additionally, certain machinery and equipment are financed from time to time by non-cancellable operating leases or capital leases. The Company believes that these sources will be sufficient to support ongoing business requirements, including capital expenditures through the current fiscal year.

The Company had working capital of $24,773,000 at July 31, 2013 compared to $25,115,000 at April 30, 2013. The ratio of current assets to current liabilities was 2.3-to-1.0 at July 31, 2013 and 2.1-to-1.0 at April 30, 2013. At July 31, 2013, advances of $4,862,000 were outstanding under the Company’s $20 million bank revolving credit facility, as compared to advances of $6,653,000 outstanding as of April 30, 2013.

The Company’s operations provided cash of $1,805,000 during the three months ended July 31, 2013. Cash was primarily provided from earnings, a decrease in accounts receivable of $1,103,000, and a decrease in inventory of $869,000, partially offset by a decrease in accounts payable and other accrued expenses of $2,105,000. The Company’s operations provided cash of $2,730,000 during the three months ended July 31, 2012. Cash was primarily provided from earnings, a decrease in accounts receivable of $1,273,000, and an increase in accounts payable and other accrued expenses of $768,000.

During the three months ended July 31, 2013, net cash of $456,000 was used in investing activities, primarily for capital expenditures. This compares to $383,000 used for investing activities during the three months ended July 31, 2012.

The Company’s financing activities used cash of $2,383,000 during the three months ended July 31, 2013, primarily for payment of $1,780,000 toward the purchase of the noncontrolling interest in a subsidiary, for repayment of short-term borrowings of $1,896,000,

 

8


and cash dividends of $260,000 paid to stockholders. This was partially offset by a net increase in long-term debt of $1,496,000 in conjunction with the replacement of the Company’s long-term loans with a new lender as discussed in Note E. The Company’s financing activities used cash of $612,000 during the three months ended July 31, 2012, primarily for repayment of short-term borrowings of $315,000 and cash dividends of $258,000 paid to stockholders.

Outlook

The Company’s ability to predict future demand for its products continues to be limited given its role as subcontractor or supplier to dealers for subcontractors. Demand for the Company’s products is also dependent upon the number of laboratory construction projects planned and/or current progress in projects already under construction. The Company’s earnings are also impacted by increased costs of raw materials, including stainless steel, wood, and epoxy resin, and whether the Company is able to increase product prices to customers in amounts that correspond to such increases without materially and adversely affecting sales. Additionally, since prices are normally quoted on a firm basis in the industry, the Company bears the burden of possible increases in labor and material costs between the quotation of an order and delivery of a product. The Company is also unable to predict the timing and strength of the global economic recovery and its short-term and long-term impact on its operations and the markets in which it competes.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995

Certain statements in this report constitute “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the “Reform Act”). Such forward-looking statements involve known and unknown risks, uncertainties and other factors that could significantly impact results or achievements expressed or implied by such forward-looking statements. These factors include, but are not limited to, economic, competitive, governmental, and technological factors affecting the Company’s operations, customer changes to product designs, customer changes to delivery dates, markets, products, services, and prices, as well as prices for certain raw materials and energy. The cautionary statements made pursuant to the Reform Act herein and elsewhere by the Company should not be construed as exhaustive. The Company cannot always predict what factors would cause actual results to differ materially from those indicated by the forward-looking statements. In addition, readers are urged to consider statements that include the terms “believes”, “belief”, “expects”, “plans”, “objectives”, “anticipates”, “intends” or the like to be uncertain and forward-looking. Over time, the Company’s actual results, performance or achievements will likely differ from the anticipated results, performance or achievements that are expressed or implied by the Company’s forward-looking statements, and such difference might be significant and harmful to stockholders’ interests. Many important factors that could cause such a difference are described under the caption “Risk Factors,” in Item 1A of the Company’s 2013 Annual Report on Form 10-K.

 

9


REVIEW BY INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

A review of the interim consolidated financial information included in this Quarterly Report on Form 10-Q for each of the three month periods ended July 31, 2013 and July 31, 2012 has been performed by Cherry Bekaert LLP, the Company’s independent registered public accounting firm. Their report on the interim consolidated financial information follows.

 

10


REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We have reviewed the accompanying consolidated balance sheet of Kewaunee Scientific Corporation and its subsidiaries (the “Company”) as of July 31, 2013, the related consolidated statements of operations, comprehensive income and cash flows for the three-month periods ended July 31, 2013 and 2012 and the related consolidated statement of stockholders’ equity for the three-month period ended July 31, 2013. These interim consolidated financial statements are the responsibility of the Company’s management.

We conducted our reviews in accordance with the standards of the Public Company Accounting Oversight Board (United States). A review of interim financial information consists principally of applying analytical procedures and making inquiries of persons responsible for financial and accounting matters. It is substantially less in scope than an audit conducted in accordance with the standards of the Public Company Accounting Oversight Board (United States), the objective of which is the expression of an opinion regarding the financial statements taken as a whole. Accordingly, we do not express such an opinion.

Based on our reviews, we are not aware of any material modifications that should be made to the interim consolidated financial statements referred to above for them to be in conformity with accounting principles generally accepted in the United States of America.

We previously audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States), the consolidated balance sheet as of April 30, 2013, and the related consolidated statements of operations, comprehensive income and stockholders’ equity, and cash flows for the year then ended (not presented herein) and in our report dated July 18, 2013, we expressed an unqualified opinion on those consolidated financial statements. In our opinion, the information set forth in the accompanying consolidated balance sheet as of April 30, 2013 is fairly stated in all material respects in relation to the consolidated financial statement from which it has been derived.

 

/s/ Cherry Bekaert LLP

Charlotte, North Carolina

September 13, 2013

 

11


Item 3. Quantitative and Qualitative Disclosures About Market Risk

There are no material changes to the disclosures made on this matter in the Company’s Annual Report on Form 10-K for the fiscal year ended April 30, 2013.

 

Item 4. Controls and Procedures

(a) Evaluation of disclosure controls and procedures

An evaluation was performed under the supervision and with the participation of the Company’s management, including the Chief Executive Officer (“CEO”) and Chief Financial Officer (“CFO”), of the effectiveness of the design and operation of the Company’s disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended) as of July 31, 2013. Based on that evaluation, the Company’s management, including the CEO and CFO, concluded that, as of July 31, 2013, the Company’s disclosure controls and procedures were adequate and effective and designed to ensure that all material information required to be filed in this quarterly report is made known to them by others within the Company and its subsidiaries.

(b) Changes in internal controls

There was no significant change in the Company’s internal control over financial reporting that occurred during the most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting.

 

12


PART II. OTHER INFORMATION

 

Item 6. Exhibits

 

3.1    Bylaws (As amended as of July 1, 2013)1
10.1    Credit and Security Agreement dated as of May 6, 2013 between Wells Fargo Bank, National Association and Kewaunee Scientific Corporation including the forms of notes executed thereunder.2
10.1A    First Amendment to Credit and Security Agreement dated July 9, 20133
10.2*    Fiscal Year 2014 Incentive Bonus Plan1
10.3*    Consulting Agreement dated June 24, 2013 between Sudhir K. Vadehra and the Company4
10.4*    Consulting Agreement dated June 24, 2013 between William A. Shumaker and the Company4
31.1    Certification of Chief Executive Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2    Certification of Chief Financial Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1    Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2    Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS    XBRL Instance Document
101.SCH    XBRL Taxonomy Extension Schema Document
101.CAL    XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF    XBRL Taxonomy Extension Definition Linkbase Document
101.LAB    XBRL Taxonomy Extension Label Linkbase Document
101.PRE    XBRL Taxonomy Extension Presentation Linkbase Document

 

* The referenced exhibit is a management contract or compensatory plan, or arrangement.
1  Filed as an exhibit to the Kewaunee Scientific Corporation Current Report on Form 8-K (Commission File No. 0-5286) filed on July 2, 2013, and incorporated herein by reference.
2  Filed as an exhibit to the Kewaunee Scientific Corporation Current Report on Form 8-K (Commission File No. 0-5286) filed on May 9, 2013, and incorporated herein by reference.
3  Filed as an exhibit to the Kewaunee Scientific Corporation Current Report on Form 8-K (Commission File No. 0-5286) filed on July 11, 2013, and incorporated herein by reference.
4  Filed as an exhibit to the Kewaunee Scientific Corporation Current Report on Form 10-K (Commission File No. 0-5286) for the fiscal year ended April 30, 2013 and incorporated herein by reference.

 

13


SIGNATURE

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

   

KEWAUNEE SCIENTIFIC CORPORATION

(Registrant)                    

Date: September 13, 2013     By  

D. Michael Parker

     

D. Michael Parker

(As duly authorized officer and Senior Vice President, Finance and Chief Financial Officer)

 

14